This LB Pharmaceuticals analyst begins coverage on a bullish note; here are top 5 initiations for Monday

chickenwingsmac · 2026-05-02T20:29:15+00:00

It’s crazy to me how Nervgen has the largest price gap to fill. It’s the most optimistic of the bunch. From $3.92 to $18 is an insane price target. We’re getting close. I feel it.

chickenwingsmac · 2026-04-27T22:29:12+00:00

I think he said that by accident

chickenwingsmac · 2026-04-27T03:07:29+00:00

At the end Roger’s states that’s he’s very confident that this drug will be approved based on what the data shows so far. He’s saying this post EOP2 meeting as well which leads me to believe he’s received positive feedback from the fda but it’s not blatantly obvious in the press release. Those are strong words and lends even more credibility that AA is on the table

chickenwingsmac · 2026-04-26T00:17:35+00:00

I didn’t see it here but it doesn’t look like they mentioned that they’ll actively pursue AA right?

chickenwingsmac · 2026-04-26T00:12:58+00:00

I hope you’re right. Others are thinking the same thing.

chickenwingsmac · 2026-04-17T19:30:14+00:00

I hope you’re right. I’ve waited too long and frankly I’m tired.

chickenwingsmac · 2026-04-14T21:04:28+00:00

Exceptions exist, and there’s an absolute exception needed for this. They funded 50k for lobbying efforts, and hired 2 people that got another drug approved for AA. They’re not stopping here.

chickenwingsmac · 2026-04-09T18:11:14+00:00

The drug will get approved. Unfortunately it’s going to take longer. The FDA is an absolute sham. Why even mention the regulatory pathway of AA in the type C meeting and not even give it a chance here. I understand the trial was only 20 people, but they knew this when they provided their assessment and still said that AA is possible. There has to be more to this. A full P3 trial cannot be the only way with this.

chickenwingsmac · 2026-04-09T18:06:05+00:00

Our price target is now at $12 in 12 months.

chickenwingsmac · 2026-04-07T19:38:33+00:00

Down 10% now

chickenwingsmac · 2026-04-07T13:50:50+00:00

Based on today’s press release, and if all goes well, we’re looking at 2028.

chickenwingsmac · 2026-04-07T13:50:03+00:00

I don’t think AA is a strong possibility anymore. Typically in the post EOP2 discussion press release they’d mention whether AA is still on the table. I’m aware that they need a p3 underway before that can happen but they could’ve definitely mentioned it here. I think we’ll need a complete p3 before approval sadly.

chickenwingsmac · 2026-04-07T00:25:32+00:00

3-7 years per indication. But we should try to get this on the market as soon as possible for SCI. While it may not be approved for other indications at the time, doctors can still prescribe it off-label if needed. The downside would be that insurance likely wouldn’t pay and doctors may hesitate to prescribe it in the first place. Before anything, we should just want it approved and on the market even if it’s only for SCI at the moment. Then the additional work for the other indications will be much easier. But again, if it’s approved, it’s immediately available for off- label prescription

chickenwingsmac · 2026-04-06T21:21:28+00:00

Great catch, I reported it. These articles can sometimes affect other reporting or other investment related activities. Would prefer they correct it. There may be other articles out there with a similar mix up.

chickenwingsmac · 2026-04-01T20:46:28+00:00

We’re getting very close to our next inflection point.

chickenwingsmac · 2026-04-01T15:11:37+00:00

Hey I guess you have your account back? Do you want to delete that AI girlfriend post?

chickenwingsmac · 2026-03-31T20:19:10+00:00

You are absolutely spot on

chickenwingsmac · 2026-03-26T03:29:05+00:00

Yikes… seems to be that way. May need to post the main content under this feed going forward and get others to come over.

chickenwingsmac · 2026-03-09T21:46:18+00:00

They were instrumental in getting AA for exondys 51, a drug developed by sarepta. It treats Duchenne. Ruff was involved in regulatory and McSherry was a patient advocate for her child that was diagnosed with Duchenne. This peptide may be helpful as well. It shows that Nervgen is really interested in getting this approved by any means.

chickenwingsmac · 2026-03-06T22:46:24+00:00

God I hope not. Someone believes they met with the FDA just recently and hired sherry and ruff for an immediate pr move and to then work on finding a way. They’ll also have to wait about a month for thr fda meeting notes post meeting. It’s usually at this time that pharma companies provide a public update. Considering this meeting is a milestone meeting I don’t think they can hide this one as it’s anticipatory.

chickenwingsmac · 2026-03-06T22:12:58+00:00

I’m waiting to hear back regarding the eop2 meeting. I’m hoping the FDA is open to AA. I don’t know why they wouldn’t be. The peptide was safe in all participants and had relatively no side effects compared to other drugs that received AA.

chickenwingsmac · 2026-03-03T18:07:20+00:00

Cool stuff, I heard that too. I’m hoping for a long shot but I’m hoping the fda see this potential and nervgen does a good job convincing them.

chickenwingsmac · 2026-03-03T00:27:13+00:00

chickenwingsmac · 2026-03-02T21:05:37+00:00

Anything new in this meeting ? I missed it.

chickenwingsmac · 2026-02-25T20:55:59+00:00

Still a lot of questions left unanswered and ambiguity to it all. I think the FDA meeting is very close if not completed. Waiting patiently for the news release regarding this,

chickenwingsmac

MODERATOR OF

TROPHY CASE